canakinumab

Ligand id: 6773

Name: canakinumab

No information available.
Summary of Clinical Use
Used to treat familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS) in patients > 4 years, and systemic juvenile idiopathic arthritis (SJIA) in patients > 2 years.
Mechanism Of Action and Pharmacodynamic Effects
A monoclonal antibody which binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors [1], but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra). The patent covering this antibody, US7446175, reports the antigenic epitope on IL-1β as the loop containing the Glu64 residue in the mature cytokine (equivalent to residue 180 of the precursor peptide) [2]
External links